World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
63
Citations
15128
World Ranking
2718
National Ranking
65

Thomas Klimkait publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Thomas Klimkait sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 282 publications — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Thomas Klimkait D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Thomas Klimkait sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 63 D-Index — 52nd percentile

52% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Thomas Klimkait is affiliated with the University of Basel in Switzerland and has a research focus primarily in the fields of Medicine and Immunology and Microbiology. Their work extensively covers subfields such as Infectious Diseases, Virology, Emergency Medicine, Epidemiology, and Molecular Biology.

The scientist's main research topics address several aspects of HIV/AIDS, including HIV/AIDS Research and Interventions, HIV Research and Treatment, HIV/AIDS drug development and treatment, and HIV-related health complications and treatments. Other significant subjects of study include SARS-CoV-2 and COVID-19 Research, HIV, Drug Use, Sexual Risk, and Hepatitis C virus research.

Thomas Klimkait has contributed to numerous peer-reviewed publications, with frequent appearances in specific scientific venues. The most common publication venues include:

  • Clinical Infectious Diseases
  • Open Forum Infectious Diseases
  • The Journal of Infectious Diseases
  • Zenodo (CERN European Organization for Nuclear Research)
  • Journal of Antimicrobial Chemotherapy

Their recent papers feature contributions to diverse high-impact journals and publications. Selected works include:

  • Cohort Profile Update: The Swiss HIV Cohort Study (SHCS), 2021, International Journal of Epidemiology
  • A highly virulent variant of HIV-1 circulating in the Netherlands, 2022, Science
  • Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV, 2022, Zurich Open Repository and Archive (University of Zurich)
  • Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy, 2023, Clinical Infectious Diseases
  • Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland, 2023, The Lancet Regional Health - Europe

Collaboration is a notable aspect of Thomas Klimkait's research career. Frequent co-authors include:

  • Huldrych F. Günthard
  • Enos Bernasconi
  • Matthias Cavassini
  • Roger D. Kouyos
  • Alexandra Calmy

Best Publications

  • Prospective Study of Polyomavirus Type BK Replication and Nephropathy in Renal-Transplant Recipients

    Hans H Hirsch;Wendy Knowles;Michael Dickenmann;Jakob Passweg

  • Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy.

    V Nickeleit;T Klimkait;I F Binet;P Dalquen

  • The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release.

    T Klimkait;K Strebel;M D Hoggan;M A Martin

  • A novel gene of HIV-1, vpu, and its 16-kilodalton product.

    Klaus Strebel;Thomas Klimkait;Malcolm A. Martin

  • Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein.

    K Strebel;T Klimkait;F Maldarelli;M A Martin

  • Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion.

    Jacqueline R. Wyatt;Timothy A. Vickers;Joseph L. Roberson;Robert W. Buckheit

  • An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication

    François Hamy;Eduard R. Felder;Gerhard Heizmann;Janis Lazdins

  • European guidelines on the clinical management of HIV-1 tropism testing

    L.P.R. Vandekerckhove;Annemarie Wensing;Rolf Kaiser;F. Brun-Vézinet

  • Effect of Offering Same-Day ART vs Usual Health Facility Referral During Home-Based HIV Testing on Linkage to Care and Viral Suppression Among Adults With HIV in Lesotho: The CASCADE Randomized Clinical Trial.

    Niklaus D. Labhardt;Niklaus D. Labhardt;Niklaus D. Labhardt;Isaac Ringera;Thabo I. Lejone;Thomas Klimkait

  • New Aza-Dipeptide Analogues as Potent and Orally Absorbed HIV-1 Protease Inhibitors: Candidates for Clinical Development

    Guido Bold;Alexander Fässler;Hans-Georg Capraro;Robert Cozens

  • Estimating the Basic Reproductive Number from Viral Sequence Data

    Tanja Stadler;Roger Kouyos;Viktor von Wyl;Sabine Yerly

  • A prospective trial of structured treatment interruptions in human immunodeficiency virus infection

    Catherine Fagard;Annette Oxenius;Huldrych Günthard;Felipe Garcia

  • Molecular Epidemiology Reveals Long-Term Changes in HIV Type 1 Subtype B Transmission in Switzerland

    Roger D. Kouyos;Viktor von Wyl;Sabine Yerly;Jürg Böni

  • A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition.

    François Hamy;Vincent Brondani;Andreas Flörsheimer;Wilhelm Stark

  • A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control

    István Bartha;Jonathan M Carlson;Chanson J Brumme;Paul J McLaren;Paul J McLaren;Paul J McLaren

  • Prospective Monitoring of BK Virus Load after Discontinuing Sirolimus Treatment in a Renal Transplant Patient with BK Virus Nephropathy

    Hans H. Hirsch;Markus Mohaupt;Thomas Klimkait

  • Determinants of HIV-1 broadly neutralizing antibody induction

    Peter Rusert;Roger D Kouyos;Claus Kadelka;Hanna Ebner

  • Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART.

    Nadine Bachmann;Chantal von Siebenthal;Valentina Vongrad;Teja Turk

  • Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey

    Sabine Yerly;Viktor von Wyl;Bruno Ledergerber;Jürg Böni

  • Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection

    Roger D Kouyos;Viktor von Wyl;Sabine Yerly;Jürg Böni

  • Emergence of HIV-1 Drug Resistance in Previously Untreated Patients Initiating Combination Antiretroviral Treatment: A Comparison of Different Regimen Types

    Viktor von Wyl;Sabine Yerly;Jürg Böni;Philippe Bürgisser

Frequent Co-Authors

Sabine Yerly
Sabine Yerly University of Geneva
Manuel Battegay
Manuel Battegay University Hospital of Basel
Huldrych F. Günthard
Huldrych F. Günthard University of Zurich
Jürg Böni
Jürg Böni University of Zurich
Enos Bernasconi
Enos Bernasconi Universita della Svizzera Italiana
Matthias Cavassini
Matthias Cavassini University of Lausanne
Roger D. Kouyos
Roger D. Kouyos University of Zurich
Pietro Vernazza
Pietro Vernazza University of St. Gallen
Hansjakob Furrer
Hansjakob Furrer University of Bern
Bruno Ledergerber
Bruno Ledergerber University of Zurich

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology in the USA opens doors to various online degrees and career options beyond traditional lab roles. For those with unique challenges, such as a criminal record, exploring what is the best degree for a convicted felon can provide valuable guidance on accessible educational paths that lead to stable careers.

Many microbiology graduates find rewarding roles in healthcare settings. Careers like becoming a functional medicine nurse practitioner offer opportunities to apply biological knowledge in patient care, with competitive salaries and growing demand. Understanding the functional medicine nurse practitioner salary can help you evaluate this pathway’s potential.

Another promising area linked to microbiology and health sciences is health information management. As a health information manager, you would oversee medical data and ensure accuracy in healthcare documentation. Learning about health information management jobs salary and career pathways can clarify the benefits of this role.

For those interested in coding medical information, obtaining a certified professional coder certification enhances employability in medical billing and coding fields. This certification can open doors to various healthcare organizations, making it a practical complement to your microbiology background.

Best Scientists Citing Thomas Klimkait

Trending Scientists

Recently Published Articles